Henn Matthew R 4

What Happened

• Matthew R. Henn, Chief Scientific Officer and EVP of Seres Therapeutics (MCRB), had 239 restricted stock units (RSUs) convert into 239 shares on Feb 15, 2026. To cover taxes tied to that vesting, Henn sold 89 shares in the open market at $8.47 each for $754 and had 239 shares reported as surrendered/converted (reported as derivative dispositions at $0).

Key Details

• Transaction date: February 15, 2026; Form 4 filed February 18, 2026.
• Open-market sale: 89 shares at $8.47/share — proceeds $754.
• RSU conversion: 239 shares acquired via conversion of RSUs (reported with price N/A).
• Withholding/net settlement: 141 shares and 98 shares reported as disposed at $0 (derivative-related dispositions totaling 239 shares).
• Plan/footnotes: Sales were effected under a Rule 10b5-1 plan (adopted April 13, 2023) solely to cover taxes related to RSU vesting. RSUs vest per the disclosed schedule (25% vested Feb 15, 2024 and Feb 15, 2025; remainder vest quarterly thereafter; RSUs convert to one share each).
• Shares owned after transaction: not specified in the provided excerpt.
• Filing timeliness: Form 4 filed Feb 18; the report does not indicate a late filing flag.

Context

• These entries reflect RSU settlement and related tax-covering actions (10b5-1 sale and shares withheld/surrendered). Such transactions are commonly routine tax-withholding events rather than directional bets on the stock. The derivative entries indicate conversion/settlement of RSUs and withholding rather than a traditional option exercise for cash.